Cagrilintide Dose Escalation Studies Phase 2 trials evaluated multiple cagrilintide doses to identify the optimal balance between efficacy and tolerability: 0.3 mg weekly Minimal efficacy, excellent tolerability 0.6 mg weekly Moderate effects, good tolerability 1.2 mg weekly Strong efficacy, acceptable side effects 2.4 mg weekly Optimal efficacy-tolerability balance 4.5 mg weekly Excessive GI side effects outweighed benefits The 2.4 mg weekly dose emerged as the standard in phase 3 trials, providing substantial metabolic benefits while maintaining an acceptable side effect profile[6]
It reduces insulin resistance, inflammation, and oxidative stress while protecting against age-related diseases like cancer and cardiovascular issues
Glucose uptake assay Glucose uptake was monitored with the fluorescent deoxyglucose analogue 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) (Thermo Fisher Scientific, San Jose, CA, USA) 47
The result is one of the most comprehensive GLP-1 programs available today
PLoS ONE 13(3):e0193921 Yang C, Mo Y, Xu E, Wen H, Wei R, Li S, Zheng J, Li W, Le B, Chen Y, Pan H (2019) Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinsons disease mouse model
Manufactured in a USA cGMP-Certified facility and tested by independent labs to ensure purity
